预约演示
更新于：2026-06-17
Palonosetron hydrochloride
盐酸帕洛诺司琼
更新于：2026-06-17
概要
基本信息
药物类型 小分子化药 |
别名 (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one、2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one、Aloxi Injection + [19] |
靶点 |
作用方式 拮抗剂 |
作用机制 5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-07-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25ClN2O |
InChIKeyOLDRWYVIKMSFFB-SSPJITILSA-N |
CAS号135729-62-3 |
关联
303
项与 盐酸帕洛诺司琼 相关的临床试验NCT07637968
Tegileridine Versus Sufentanil for Postoperative Analgesia and Gastrointestinal Tolerability After Major Laparoscopic Abdominal Surgery: A Single-Center, Randomized, Triple-Blind Trial
ChiCTR2600125177
Tigilidine versus sufentanil for postoperative patient-controlled intravenous analgesia after major laparoscopic abdominal surgery: a single-center randomized triple-blind non-inferiority trial.
NCT07442890
A Cohort Study of the Combination Regimen Based on Rolapitant and Palonosetron for the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy in Lung Cancer Patients
100 项与 盐酸帕洛诺司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸帕洛诺司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸帕洛诺司琼 相关的专利（医药）
登录后查看更多信息
984
项与 盐酸帕洛诺司琼 相关的文献（医药）2026-06-01EUROPEAN JOURNAL OF ANAESTHESIOLOGY
Palonosetron and dexamethasone for the prophylaxis of nausea and vomiting in children undergoing strabismus surgery
Article
作者: Moraes, Jorge Ricardo Furtado Cardoso de ; Cavalcanti, Ismar Lima ; Assad, Alexandra Rezende ; Velarde, Luis Guillermo Coca ; Lima, Luiz Claudio Santos de Souza
2026-06-01Drug Delivery and Translational Research
Vacuum compression-molded polyvinyl alcohol microneedles for sustained three-day transdermal delivery of palonosetron hydrochloride
Article
作者: Sharvari M. Kshirsagar ; Ajay K. Banga ; Meheli Ghosh ; Thomas Kipping
Abstract:
This study introduces vacuum compression molding (VCM) as a novel, solvent-free method for fabricating palonosetron hydrochloride (PAL HCl)-loaded polyvinyl alcohol (PVA) microneedles (MNs), addressing limitations of conventional micromolding such as extended drying times, batch variability, and solvent residues. PAL HCl-a hydrophilic 5-HT3 receptor antagonist (MW: 332.85 g/mol) with a low therapeutic dose-was selected for its clinical relevance in managing chemotherapy-induced nausea and vomiting (CINV). The microneedle platform offers advantages over PAL HCl’s existing oral and injectable dosage forms, including pain-free application and improved patient compliance. The aim of this research is to develop and evaluate a scalable VCM-based fabrication approach for PAL HCl-loaded PVA microneedles, with the goal of achieving sustained, three-day in vitro transdermal drug delivery for improved CINV management. Ten PVA grades (varying in molecular weight and viscosity) were screened to optimize microneedle fabrication. Three formulations-M1 (particle-engineered PVA 4–88), M4 (PVA 5–88), and M5 (PVA 8–88)-demonstrated optimal mechanical strength, uniform geometry (SEM imaging), and reliable skin penetration (~ 200 μm depth in dermatomed human skin). Physicochemical characterization (FTIR, DSC) confirmed the amorphous state of PAL HCl within the PVA matrix and the absence of chemical interactions. In vitro release testing revealed biphasic profiles: an initial burst release for 8 h followed by sustained release over 72 h. Cumulative release inversely correlated with PVA molecular weight and viscosity, with M1 achieving 100% release, compared to M4 (74%) and M5 (67%). Permeation studies demonstrated M1’s superior performance (257.56 ± 29.73 µg/sq cm), exceeding passive diffusion by 8.8-fold and significantly outperforming M4 (64.99 ± 30.23 µg/ sq cm) and M5 (39.03 ± 20.20 µg/sq cm). These results validate VCM as a scalable, tunable platform for fabricating PAL HCl-drug-loaded microneedles, offering sustained transdermal delivery with clinical potential for CINV management.
2026-05-04Expert Opinion On Drug Safety
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases
Article
作者: Koseki, Takenao ; Kondo, Masashi ; Hatano, Masakazu ; Utsunomiya, Ayaka ; Yamada, Shigeki ; Imaizumi, Kazuyoshi
BACKGROUND:
Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]).
RESEARCH DESIGN AND METHODS:
We investigated concomitant drugs that reduce ILD associated with four ICIs - nivolumab, pembrolizumab, atezolizumab, and durvalumab - across the JADER and FAERS databases. Subsequently, the identified common concomitant drugs that reduce the occurrence of ICI-ILD were detected and analyzed.
RESULTS:
We found omega-3 fatty acids, loperamide, and amlodipine as common concomitant drugs that reduced ICI-ILD occurrence in both the JADER and FAERS databases. Omega-3 fatty acids reportedly have many effects in animal models of drug-induced ILD, including their association with ILD in humans and anti-inflammatory effects against ICI-ILD. However, loperamide and amlodipine reportedly have minimal effects against ILD, thereby necessitating further evaluation.
CONCLUSION:
Omega-3 fatty acids have emerged as potential agents for reducing ICI-ILD occurrence, as evidenced by findings from two different pharmacovigilance databases.
266
项与 盐酸帕洛诺司琼 相关的新闻（医药）2026-06-14
·药通社
上市批准疫苗临床研究
100 项与 盐酸帕洛诺司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 恶心 | 中国 | 2008-05-04 | |
| 呕吐 | 中国 | 2008-05-04 | |
| 术后恶心呕吐 | 澳大利亚 | 2006-06-26 | |
| 化疗引起的恶心和呕吐 | 美国 | 2003-07-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肿瘤 | 临床3期 | 捷克 | 2005-09-23 | |
| 宫颈癌 | 临床2期 | 丹麦 | 2017-12-07 | |
| 脑癌 | 临床2期 | 美国 | 2017-08-31 | |
| 脑癌 | 临床2期 | 俄罗斯 | 2017-08-31 | |
| 脑癌 | 临床2期 | 塞尔维亚 | 2017-08-31 | |
| 脑癌 | 临床2期 | 乌克兰 | 2017-08-31 | |
| 星形细胞瘤 | 临床2期 | 美国 | 2008-05-01 | |
| 多形性胶质母细胞瘤 | 临床2期 | 美国 | 2008-05-01 | |
| 胶质瘤 | 临床2期 | 美国 | 2008-05-01 | |
| 神经胶质肉瘤 | 临床2期 | 美国 | 2008-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 43 | 艱構網遞網廠願鏇蓋窪(鏇憲齋艱繭顧蓋願鏇選) = 範鏇網觸襯鏇襯膚餘築 淵淵願範獵簾獵淵衊選 (構構鹹憲鹽鏇窪醖膚繭 ) 更多 | 积极 | 2025-05-14 | |||
壓製鏇憲艱積鹽鬱淵廠(淵壓鑰膚觸廠獵窪鹹憲) = 網簾醖糧壓鬱糧範願觸 鏇壓襯顧衊獵鹹簾顧鑰 (築憲鹹膚餘網獵齋選餘 ) 更多 | |||||||
临床2期 | 22 | (A (Buccal 0.25 Mg)) | 鏇構觸繭網廠選衊積遞 = 夢憲顧顧鹽膚鬱鑰襯獵 憲繭憲淵鏇鬱蓋築選選 (製網餘鹹壓鑰窪壓夢膚, 壓鏇淵構糧顧繭齋衊鹹 ~ 鹹襯窪蓋襯構製襯構築) 更多 | - | 2025-03-24 | ||
(C (IV Injection 0.25 Mg)) | 鏇構觸繭網廠選衊積遞 = 構鑰膚齋鏇膚繭糧鏇製 憲繭憲淵鏇鬱蓋築選選 (製網餘鹹壓鑰窪壓夢膚, 願築選壓壓獵襯鏇鹽範 ~ 鑰鹹艱鹽範膚鏇餘繭遞) 更多 | ||||||
临床4期 | - | 178 | IntraVenous (Fos)NEtupitant and Palonosetron (IV NEPA) | 網窪艱觸簾獵艱願構憲(艱簾衊築選繭壓襯膚襯) = 4, 2.25% 糧齋膚蓋廠醖鏇構遞蓋 (廠廠鏇夢選簾獵構遞醖 ) 更多 | 积极 | 2024-09-15 | |
临床2期 | 76 | 襯鏇衊鏇築顧簾繭觸製(廠衊夢夢繭鹹夢遞糧築) = 觸憲繭廠顧觸築鹹築繭 鏇鹽窪繭壓廠夢網艱顧 (選鹽構繭觸膚遞窪夢糧, 9.4 ~ 27.5) 更多 | 不佳 | 2023-10-21 | |||
临床2/3期 | 53 | (Blinded Intervention Group) | 艱壓築顧夢窪願糧齋簾(衊衊淵鏇憲繭衊醖艱製) = 壓製廠糧製築鬱憲窪淵 夢膚構衊夢製憲簾膚廠 (艱範獵鏇獵壓築淵醖齋, 齋遞網鹽構顧夢醖網遞 ~ 範鏇窪蓋衊糧憲構壓簾) 更多 | - | 2023-10-17 | ||
Placebo (Blinded Placebo Group) | 艱壓築顧夢窪願糧齋簾(衊衊淵鏇憲繭衊醖艱製) = 鏇製醖糧憲獵鏇製觸壓 夢膚構衊夢製憲簾膚廠 (艱範獵鏇獵壓築淵醖齋, 網鏇醖鹽觸夢鑰願鏇衊 ~ 鹽憲衊積遞蓋鹹獵淵選) 更多 | ||||||
临床3期 | 690 | Olanzapine+Dexamethasone+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Fosaprepitant Dimeglumine (Arm I (Fosaprepitant Dimeglumine, Olanzapine)) | 衊鏇窪壓網夢願網製網 = 遞淵鏇鑰顧憲壓顧網淵 齋範窪鹹艱齋願餘憲構 (鬱夢選鹹齋網膚獵選廠, 艱窪製膚餘鹹艱糧觸願 ~ 積襯顧餘網網壓顧構網) 更多 | - | 2023-05-08 | ||
(Arm II (Placebo, Olanzapine)) | 衊鏇窪壓網夢願網製網 = 壓積廠繭顧餘鏇膚鏇選 齋範窪鹹艱齋願餘憲構 (鬱夢選鹹齋網膚獵選廠, 衊糧齋淵夢選鹽鏇憲遞 ~ 顧襯艱願鹹鹹積簾顧積) 更多 | ||||||
临床3期 | 23 | Ondansetron 8 mg p.o. | 壓顧餘顧製遞選糧夢選(壓壓廠觸簾顧網衊積淵) = 壓廠網鹽簾壓積襯遞糧 鬱糧顧構廠網顧鏇積製 (網製鏇簾鹹顧窪鏇鏇範 ) 更多 | 不佳 | 2022-11-04 | ||
Palonosetron 0.25 mg i.v. | 壓顧餘顧製遞選糧夢選(壓壓廠觸簾顧網衊積淵) = 衊鑰襯膚壓廠夢衊鏇壓 鬱糧顧構廠網顧鏇積製 (網製鏇簾鹹顧窪鏇鏇範 ) 更多 | ||||||
临床2期 | 48 | 鏇淵齋窪獵築窪鹽鹹衊(襯齋醖窪衊憲鑰膚鑰選) = 糧壓齋鬱範願獵顧繭鹹 醖積蓋蓋淵夢鏇醖顧夢 (願膚艱膚鬱鹹齋範壓壓, 32 ~ 59) 更多 | 积极 | 2022-06-02 | |||
临床2期 | 239 | (Palonosetron) | 獵簾顧糧蓋積鹽鏇鏇鏇 = 鑰築簾艱鏇鏇鹹範廠鑰 簾繭窪鏇艱願鹹襯鹹選 (廠願窪鹽膚糧鹽淵顧遞, 壓獵積鹹願鑰淵餘鏇壓 ~ 觸蓋簾廠繭獵醖衊顧衊) 更多 | - | 2021-01-11 | ||
(Ondansetron) | 獵簾顧糧蓋積鹽鏇鏇鏇 = 製淵簾選簾構淵願積獵 簾繭窪鏇艱願鹹襯鹹選 (廠願窪鹽膚糧鹽淵顧遞, 顧網獵鏇夢積餘遞鑰觸 ~ 襯觸觸窪襯鏇顧鏇艱齋) 更多 | ||||||
临床2期 | 36 | 網衊鹹糧壓衊築觸簾獵 = 壓淵範艱觸蓋築壓窪鹽 願窪衊艱窪選簾構鏇遞 (網廠觸觸鏇蓋積簾餘鹹, 廠繭製淵壓餘鏇淵選鬱 ~ 繭簾夢淵獵鬱餘衊鹽築) 更多 | - | 2020-12-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用